Denali Therapeutics Inc. — Director's Dealing 2021

Jun 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2021-06-01

Reporting Person: Cole Douglas G. (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-06-01	Common Stock	M	3253	$0.00	Acquired	3253	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-01	Restricted Stock Units	$	M	3253	Disposed		Common Stock (3253)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer.

F2: 100% of the restricted stock units shall vest upon the earlier of (i) the one year anniversary of the grant date or (ii) the day preceding the Issuer's next annual meeting of stockholders occurring after the grant date.